Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Ahead of President Donald Trump's so-called "Liberation Day" tariffs, more tariffs on Brazil and India are taking effect ...

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

In this week’s edition of InnovationRx, we look at a biotech entrepreneur treating a rare genetic disease, new tech aimed at ...

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Swiss goods could soon be slapped with 39% tariffs — but Switzerland has further challenges to face when it comes to the Trump administration.

RFK Jr. announced that the U.S. government’s emergency preparedness agency will no longer fund work on mRNA vaccines ...

President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within ...

Learn more about whether Amneal Pharmaceuticals, Inc. or Ocular Therapeutix, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Kennedy said Tuesday that the terminated contracts were worth nearly $500 million. Among them is an award to the University ...

For 2025, Charles River reduced its net income projection to a range between $4.25 and $4.65 a share from a prior per-share target of $4.35 to ...